U.S. FDA issues latest in series of warning letters to Indian drugmakers

03/11/2014 | Bloomberg · Regulatory Focus

The U.S. FDA issued a warning letter to India-based Canton Laboratories on Feb. 27 for such violations as falsified test results and failure to prevent contamination. Earlier, the FDA banned factories owned by Ranbaxy and Wockhardt from supplying drugs to the U.S. As part of its stepped-up enforcement of quality and safety, the FDA has issued at least eight other official warning letters since 2013 to Indian drug companies dealing with data integrity issues.

View Full Article in:

Bloomberg · Regulatory Focus

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY